Literature DB >> 27703051

Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up.

A Bortoluzzi1, F Furini1, F Campanaro1, M Govoni1.   

Abstract

Objectives The objectives of this study were to analyse the performance of the Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria for systemic lupus erythematosus (SLE) in a large cohort of undifferentiated connective tissue disease (UCTD) population at onset of the disease and during a long-term follow-up of 15 years (1999-2013) and to evaluate the transition from UCTD to SLE, according to American College of Rheumatology (ACR) 1997 and SLICC 2012 classification criteria. Methods A cohort of patients who met the classification criteria proposed by Mosca et al. for UCTD, were analysed. The SLICC 2012 classification criteria for SLE were retrospectively applied to each patient at the time of the diagnosis (T0) and also periodically re-applied and compared to ACR 1997 criteria at three different time points in the follow-up. Results 329 patients were enrolled. According to inclusion criteria at T0 no patient met the SLE/ACR criteria, whilst, retrospectively applying the SLE/SLICC criteria, 44 patients already satisfied this set of criteria for SLE. During the follow-up 23 new patients reached the SLE/SLICC criteria and 14 patients met the ACR criteria with a stable rate of progression to SLE over time. Acute or subacute skin rash, antiphospholipid antibody (aPL) positivity and serositis were the variables correlated to the evolution to SLE. Conclusions In our UCTD population, the application of SLICC classification criteria for SLE at disease onset allowed identification of a proportion of otherwise missed SLE cases; during follow-up, and compared with ACR criteria, SLICC criteria expanded the number of patients classifiable as SLE otherwise classified as UCTD.

Entities:  

Keywords:  SLICC classification criteria; Systemic lupus erythematosus; undifferentiated connective tissue disease (UCTD)

Mesh:

Year:  2016        PMID: 27703051     DOI: 10.1177/0961203316671814

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

Review 1.  Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.

Authors:  Savino Sciascia; Dario Roccatello; Massimo Radin; Ioannis Parodis; Jinoos Yazdany; Guillermo Pons-Estel; Marta Mosca
Journal:  Nat Rev Rheumatol       Date:  2021-11-11       Impact factor: 20.543

2.  SLE: reconciling heterogeneity.

Authors:  Michael D Lockshin; Medha Barbhaiya; Peter Izmirly; Jill P Buyon; Mary K Crow
Journal:  Lupus Sci Med       Date:  2019-02-04

3.  Validation of the new classification criteria for systemic lupus erythematosus on a patient cohort from a national referral center: a retrospective study.

Authors:  Marija Bakula; Nada Čikeš; Branimir Anić
Journal:  Croat Med J       Date:  2019-08-31       Impact factor: 1.351

Review 4.  Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?

Authors:  Wietske M Lambers; Johanna Westra; Marcel F Jonkman; Hendrika Bootsma; Karina de Leeuw
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-05       Impact factor: 4.794

5.  Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.

Authors:  Rosalind Ramsey-Goldman; Roberta Vezza Alexander; Elena M Massarotti; Daniel J Wallace; Sonali Narain; Cristina Arriens; Christopher E Collins; Amit Saxena; Chaim Putterman; Kenneth C Kalunian; Tyler O'Malley; Thierry Dervieux; Arthur Weinstein
Journal:  Arthritis Rheumatol       Date:  2019-11-25       Impact factor: 10.995

Review 6.  Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence.

Authors:  Georges El Hasbani; Mario Viola; Savino Sciascia; Ali T Taher; Imad Uthman
Journal:  Rheumatol Ther       Date:  2021-01-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.